Claims for Patent: 5,616,560

Summary for Patent: 5,616,560

Title:	Methods for the treatment of osteoporosis using bisphosphonates and parathyroid hormone
Abstract:	The present invention provides methods of increasing bone mass in a human or other animal subject afflicted with osteoporosis, comprising a thirty(30)-day treatment period, comprised of a parathyroid hormone administration regimen and a bisphosphonate administration regimen, wherein (a) said parathyroid hormone administration regimen comprises the administration to said subject of parathyroid hormone at one or more level of from about 4 IU/kg per day to about 15 IU/kg per day that said parathyroid hormone is administered, provided that said parathyroid hormone is administered at least one day every seven days of every said thirty(30)-day treatment periods; and wherein (b) said bisphosphonate administration regimen comprises the administration to said subject of a bisphosphonate at a level of from about 0.0005 mgP/kg to about 1.0 mgP/kg per day that said bisphosphonate is administered, provided that said bisphosphonate is administered at least 1 day of every said thirty(30)-day treatment period.
Inventor(s):	Geddes; Ann D. (Norwich, NY), Boyce; Rogely W. (Pottstown, PA)
Assignee:	The Procter & Gamble Company (Cincinnati, OH)
Application Number:	08/619,103
Patent Claims:	1. A method of increasing bone mass in a human or other animal subject afflicted with osteoporosis, consisting essentially of a thirty(30)-day treatment period, consisting essentially of a parathyroid hormone administration regimen and bisphosphonate administration regimen, wherein (a) said parathyroid hormone administration regimen consists essentially of the administration to said subject of parathyroid hormone at a level of from about 4 IU/kg per day to about 15 IU/kg per day that said parathyroid hormone is administered, provided that said parathyroid hormone is administered at least one day every seven days of every said thirty(30)-day treatment period; and wherein (b) said bisphosphonate administration regimen consists essentially of the administration to said subject of a bisphosphonate at a level of from about 0.0005 mgP/kg to about 1.0 mgP/kg per day that said bisphosphonate is administered, provided that said bisphosphonate is administered at least 1 day of every said thirty(30)-day treatment period. 2. A method of increasing bone mass in a human or other mammal subject afflicted with osteoporosis, according to claim 1, before a significant loss of net skeletal mass has occurred in said subject. 3. A method of increasing bone mass in a human or other mammal subject afflicted with osteoporosis, according to claim 1, wherein said bone-active phosphonate is a bisphosphonic acid, or a pharmaceutically-acceptable salt or ester thereof. 4. A method of increasing bone mass in a human or other mammal subject afflicted with osteoporosis, according to claim 1, wherein said bisphosphonic acid is of the formula: ##STR7## wherein: n is an integer from 0 to 7; R.sup.1 is hydrogen, chloro, amino, or hydroxy; X is --NH--, oxygen, or a single bond; R.sup.2 is a 5- to 7-membered herocycle having from 1 to 3 heteroatoms, amino, amino substituted with one or two lower alkyl groups, or hydrogen; and their pharmaceutically-acceptable salts and esters. 5. A method of increasing bone mass in a human or other mammal subject afflicted with osteoporosis, according to claim 1, wherein said bisphosphonic acid is selected from the group consisting of: 1-hydroxyethane-1,1-bisphosphonic acid; dichoromethane bisphosphonic acid; 3-amino-1-hydroxypropane-1,1-bisphosphonic acid; 6-amino-1-hydroxyhexane-1,1-bisphosphonic acid; 4-amino-1-hydroxybutane-1,1-bisphosphonic acid; 2-(3-pyridyl)-1-hydroxyethane-1,1-bisphosphonic acid; 2-(N-imidazoyl)-1-hydroxyethane-1,1-bisphosphonic acid; 3-(N-pentyl-N-methlamino)-1-hydroxyethane-1,1-bisphosphonic acid; 3-(N-pyrollidino)-1-hydroxypropane-1,1-bisphosphonic acid; N-cycloheptylaminomethanebisphosphonic acid; S-(p-chlorophenyl)thiomethanebisphosphonic acid; (7-dihydro-1-pyridine)methanebisphosphonic acid; (7-dihydro-1-pyridine)hydroxymethanebisphosphonic acid; (6-dihydro-2-pyridine)hydroxymethanebisphosphonic acid; 2-(6-pyrolopyridine)-1-hydroxyethane-1,1-bisphosphonic acid; 2-(2-pyridyl)-1-hydroxy-ethane-1,1-bisphosphonic acid; and pharmaceutically-acceptable salts and esters thereof. 6. A method of increasing bone mass in a human or other mammal subject afflicted with osteoporosis, according to claim 5, wherein said bisphosphonic acid is 1-hydroxyethane-1,1-bisphosphonic acid, or a pharmaceutically acceptable salt or ester thereof. 7. A method of increasing bone mass in a human or other mammal subject afflicted with osteoporosis, according to claim 5, wherein said bisphosphonic acid is 2-(3-pyridyl)-1-hudroxethane-1,1-bisphosphonic acid, or a pharmaceutically acceptable salt or ester thereof. 8. A method of increasing bone mass in a human or other mammal subject afflicted with osteoporosis, according to claim 1, wherein said bone-active phosphonate is a phosphonoalkylphosphinate, or a pharmaceutically-acceptable salt or ester thereof. 9. A method of increasing bone mass in a human or other mammal subject afflicted with osteoporosis, according to claim 8, wherein said phosphonoalkylphosphinate is selected from the group consisting of: N-(2'-(3'-methyl)-pyridinyl)aminomethane phosphonomethylphosphinic acid; N-(2'-(5'-methyl)-pyridinyl)aminomethane phosphonomethylphosphinic acid; N-(2'-(3'-methyl)-piperidinylidene)aminomethane phosphonomethylphosphinic acid; N-(2'-(5'-methyl)-piperidinylidene)aminomethane phosphonomethyl phosphinic acid; 2-(2'-pyridinyl)ethane-1-phosphono-1-methylphosphinic acid; 2-(2'-piperidinyl)ethane-1-phosphono-1-methylphosphinic acid; 2-(p-aminophenyl)-1-hydroxy-ethane-1-phosphono-1-methylphosphinic acid; 2-(m-aminophenyl)-1-hydroxy-ethane-1-phosphono-1-methylphosphinic acid; N-(1-(5-amino-2-methyl-1-oxo)-pentyl)aminomethane phosphonomethylphosphinic acid; N-(2'-(3'-methyl)-piperidinylidene)aminomethane phosphonobutylphosphinic acid; S-(2'-pyridinyl)thiomethane phosphonomethylphosphinic acid; and 2-(2-pyridyl)-1-hydroxyethane-1-phosphono-1-methylphosphinic acid; 2-(3-pyridyl)-1-hydroxy ethane-1-phosphono-1-methylphosphinic acid; 2-(N-imidazoyl)-1-hydroxy ethane-1-phosphono-1-methylphosphinic acid; 3-(N-pentyl-N-methylamino)-1-hydroxpropane-1-phosphono-1-methyl phosphinic acid; 4-amino-1-hydroxybutane-1-phosphono-1-methylphosphinic acid; 3-(N-pyrollidino)-1-hydroxypropane-1-phosphono-1-methyl phosphinic acid; N-cycloheptylaminomethanephosphonomethylphosphinic acid; S-(p-chlorophenyl)thiomethanephosphonomethylphosphinic acid; (7-dihydro-1-pyridine)methanephosphonomethylphosphinic acid; (7-dihydro-1-pyridine)hydroxymethanephosphonomethyl phosphinic acid; (6-dihydro-2-pyridine)hydroxymethanephosphonomethylphosphinic acid; 2-(6-pyrolopyridine)-1-hydroxyethane-1-phosphono-1-methylphosphinic acid; and pharmaceutically-acceptable salts and esters thereof. 10. A method of increasing bone mass in a human or other mammal subject afflicted with osteoporosis, according to claim 1, wherein said parathyroid hormone is selected from the group consisting of h PTH (1-38), h PTH (1-34) and h PTH (1-37). 11. A method of increasing bone mass in a human or other mammal subject afflicted with osteoporosis, according to claim 1, wherein said parathyroid hormone is administered every day of said thirty(30)-day treatment period. 12. A method of increasing bone mass in a human or other mammal subject afflicted with osteoporosis, according to claim 1, wherein said parathyroid hormone is administered every other day of said thirty(30)-day treatment period. 13. A method of increasing bone mass in a human or other mammal subject afflicted with osteoporosis, according to claim 1, wherein said parathyroid hormone is administered every third day of said thirty(30)-day treatment period. 14. A method of increasing bone mass in a human or other mammal subject afflicted with osteoporosis, according to claim 1, wherein said bisphosphonate is administered every other day of said thirty(30)-day treatment period. 15. A method of increasing bone mass in a human or other mammal subject afflicted with osteoporosis, according to claim 1, wherein said bisphosphonate is administered every third day of said thirty(30)-day treatment period. 16. A method of increasing bone mass in a human or other mammal subject afflicted with osteoporosis, according to claim 1, wherein said bisphosphonate is administered every day of said thirty(30)-day treatment period. 17. A method of increasing bone mass in a human or other mammal subject afflicted with osteoporosis, consisting essentially of one or more thirty(30)-day treatment periods, comprised of a parathyroid hormone administration regimen, wherein said parathyroid hormone is a species of parathyroid hormone having 1-38 amino acid units, and bisphosphonate administration regimen, wherein, said bisphosphonate is 2-(3-pyridyl)-1-hydroxyethane-1,1-bisphosphonate, wherein, (a) said parathyroid hormone administration regimen comprises the administration to said subject of said parathyroid hormone at a level of from about 4 IU/kg per day to about 15 IU/kg per day that said parathyroid hormone is administered, provided that said parathyroid hormone is administered at least one day every seven days of every said thirty(30)-day treatment period; and wherein (b) said bisphosphonate administration regimen comprises the administration to said subject of said bisphosphonate at a level of from about 0.0005 mgP/kg to about 1.0 mgP/kg per day that said bisphosphonate is administered, provided that said bisphosphonate is administered at least 1 day of every said thirty(30)-day treatment period. 18. A method of increasing bone mass in a human or other mammal subject afflicted with osteoporosis, according to claim 17, before a significant loss of net skeletal mass has occurred in said subject. 19. A method of increasing bone mass in a human or other mammal subject afflicted with osteoporosis, according to claim 17, wherein said parathyroid hormone is administered every day of said thirty(30)-day treatment period. 20. A method of increasing bone mass in a human or other mammal subject afflicted with osteoporosis, according to claim 17, wherein said parathyroid hormone is administered every other day of said thirty(30)-day treatment period. 21. A method of increasing bone mass in a human or other mammal subject afflicted with osteoporosis, according to claim 17, wherein said parathyroid hormone is administered every third day of said thirty(30)-day treatment period. 22. A method of increasing bone mass in a human or other mammal subject afflicted with osteoporosis, according to claim 17, wherein said bisphosphonate is administered every other day of said thirty (30)-day treatment period. 23. A method of increasing bone mass in a human or other mammal subject afflicted with osteoporosis, according to claim 17, wherein said bisphosphonate is administered every third day of said thirty(30)-day treatment period. 24. A method of increasing bone mass in a human or other mammal subject afflicted with osteoporosis, according to claim 17, wherein said bisphosphonate is administered every day of said thirty(30)-day treatment period.

Details for Patent 5,616,560

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Nps Pharmaceuticals, Inc.	NATPARA	parathyroid hormone	For Injection	125511	01/23/2015		2011-12-17